Lee, Chee Khoon

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 3,379

Checkpoint inhibitors in metastatic EGFR-mutated non–small cell lung cancer-a meta-analysis

Lee, C. K., Man, J., Lord, S., Links, M., Gebski, V., Mok, T., & Yang, J. C.-H. (2017) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers

Cited by 839

Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis

Lee, C. K., Man, J., Lord, S., Cooper, W., Links, M., Gebski, V., Herbst, R. S., Gralla, R. J., Mok, T., & Yang, J. C.-H. (2018) · JAMA Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 598

Impact of Specific Epidermal Growth Factor Receptor ( EGFR ) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR -Mutant Lung Cancer: A Meta-Analysis

Lee, C. K., Wu, Y.-L., Ding, P. N., Lord, S. J., Inoue, A., Zhou, C., Mitsudomi, T., Rosell, R., Pavlakis, N., Links, M., et al. (2015) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 327

ChIP-Enrich: gene set enrichment testing for ChIP-seq data

Welch, R. P., Lee, C., Imbriano, P. M., Patil, S., Weymouth, T. E., Smith, R. A., Scott, L. J., & Sartor, M. A. (2014) · Nucleic Acids Research

Bioinformatics and Genomic NetworksGenomics and Chromatin Dynamics

Cited by 151

Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer

Price, T. J., Bruhn, M. A., Lee, C. K., Hardingham, J. E., Townsend, A. R., Mann, K. P., Simes, J., Weickhardt, A., Wrin, J. W., Wilson, K., et al. (2015) · British Journal of Cancer

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 39

Molecular and Clinical Predictors of Improvement in Progression‐free Survival with Maintenance PARP Inhibitor Therapy in Women with Platinum‐sensitive, Recurrent Ovarian Cancer: A Meta‐analysis

Lee, C. K., Friedlander, M. L., Tjokrowidjaja, A., Ledermann, J. A., Coleman, R. L., Mirza, M. R., Matulonis, U. A., Pujade‐Lauraine, E., Bloomfield, R., Goble, S., et al. (2021) · Cancer

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 36